Neurocognitive assessment in patients with brain oligometastases receiving targeted radiotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on patients diagnosed with brain oligometastases who are receiving hypofractionated stereotactic radiotherapy (HF-SRT). The aim is to evaluate the neurocognitive functions of these patients, particularly in relation to the potential cognitive decline associated with conventional whole-brain radiation therapy. By utilizing HF-SRT, the study seeks to mitigate the adverse effects on cognitive health that can arise from traditional treatment methods. Participants will be monitored for their cognitive performance following treatment to assess the effectiveness of this approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with pathologically-confirmed non-hematopoietic malignancy who are referred for postoperative adjuvant or therapeutic hypofractionated stereotactic radiotherapy (HF-SRT).
* A Fair/good performance status no worse than Eastern Cooperative Group (ECOG) of 2 or an acceptable performance status of Karnofsky Score (KPS) at least 70.
* The number and extent of brain metastatic lesions should be no more than three metastatic foci with a greatest diameter no more than 4 cm shown on pre-radiotherapy MRI; namely, that is the clinical setting of oligometastatic brain disease or brain oligometastases.

Exclusion Criteria:

* Patients with their primary cancer arising from hematological malignancies (i.e., malignant lymphomas, leukemia), germ cell tumors, or malignant meningiomas
* Patients with MRI-identified metastasis within 5 mm peri-hippocampally
* Patients with metastasis involving the brain stem
* Clinical suspicion of leptomeningeal spreading
* History of prior radiotherapy including stereotactic radiosurgery delivered to brain/head region for any reasons

Where it's running

• Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting
• Chang Gung Memorial Hospital
  Taoyuan, Taiwan Recruiting

Study contacts

• Study coordinator: Chi-Cheng Chuang, M.D.
• Email: ccc2915@cgmh.org.tw
• Phone: +886-33281200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Tarlatamab for Small Cell Lung Cancer with Brain Metastases

  This phase II study tests whether tarlatamab can help adults with small cell lung cancer that has spread to the brain, by treating both systemic disease and brain tumors.

  Recruiting at 3 sites Phase 2 Maastricht University Medical Center · Amsterdam and 3 other locations · NCT07402343

• AI-assisted diagnosis for malignant brain tumors

  This project will test an AI system that uses routine preoperative MRI scans to automatically segment and classify malignant brain tumors in adults to help guide diagnosis and care.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang and 1 other locations · NCT07198256

• Same-day stereotactic radiation with reduced planning margins for growing or changing brain metastases

  This trial will try to see if doing MRI planning and stereotactic radiation on the same day, with either a 0 mm or 1 mm treatment margin, helps adults with growing or unstable brain metastases stay on target and reduce side effects.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07132190

• Preventing first seizures with levetiracetam in patients with motor cortex brain metastases

  This test will try giving levetiracetam to adults with motor cortex brain metastases who have never had a seizure to see if it prevents a first seizure compared with not giving the drug.

  Recruiting Phase 2 Brigham and Women's Hospital · Boston, Massachusetts · NCT07130786

• Avoiding brain radiation when systemic therapy already targets brain metastases

  This pilot trial tests whether patients with brain metastases who respond to systemic therapy can skip brain radiation.

  Recruiting Phase 2 University of Vermont Medical Center · Burlington, Vermont · NCT06974370

• Using ex vivo pharmacoscopy to guide treatment for brain metastases

  This project will test whether pharmacoscopy, a lab test that screens a patient's tumor cells against many drugs, can help pick effective treatments for adults having surgery for brain metastases.

  Recruiting at 2 sites Phase 2 University of Zurich · Basel and 2 other locations · NCT06620380

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.